Dexcom Q1 ’20 Earnings Update; Dexcom G7 CGM Delayed; Eversense MRI Safety Approval in EU

Dexcom hosted its Q1 ’20 earnings call and provided updates to its diabetes business, including a disclosure that the company had a record number of new patient starts in Q1 ’20. Separately, Senseonics announced it received conditional approval for use of Eversense implantable CGMs while patients undergo MRI procedures. Below, FENIX provides highlights and insights from the call including thoughts on Dexcom’s COVID-19 response.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.